Welcome to our dedicated page for Lexeo Therapeutics SEC filings (Ticker: LXEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lexeo Therapeutics, Inc. (LXEO) SEC filings page on Stock Titan aggregates the company’s public regulatory documents from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret key disclosures. As a Nasdaq-listed, clinical stage genetic medicine company, Lexeo uses filings such as Forms 8-K, 10-Q, and 10-K to report material events, financial results, and risk factors related to its gene therapy programs and corporate activities.
In its 8-K filings, Lexeo has reported items such as quarterly financial results, equity financings through underwritten public offerings and concurrent private placements, material definitive agreements like underwriting and securities purchase agreements, and registration rights agreements related to pre-funded warrants. The company also uses 8-Ks to furnish press releases that provide interim clinical and regulatory updates for its lead programs, LX2006 in Friedreich ataxia (FA) cardiomyopathy and LX2020 in PKP2-associated arrhythmogenic cardiomyopathy.
Filings also describe Lexeo’s interactions with the FDA, including feedback on potential accelerated approval pathways, participation of LX2006 in the Chemistry, Manufacturing, and Controls Development and Readiness Pilot program, and regulatory designations such as Breakthrough Therapy, RMAT, Orphan Drug, Rare Pediatric Disease, and Fast Track. Corporate governance matters, executive appointments, compensation arrangements, and stockholder meeting results are likewise documented in SEC reports.
On Stock Titan, investors can review these filings alongside AI-generated highlights that summarize complex sections, helping to identify information on clinical development plans, capital structure changes, and other material disclosures. Real-time updates from EDGAR, combined with structured access to forms such as 10-K annual reports, 10-Q quarterly reports, and 8-K current reports, support deeper analysis of Lexeo’s regulatory and financial reporting history.
BlackRock, Inc. has filed a Schedule 13G reporting a passive ownership stake in Lexeo Therapeutics, Inc. common stock. BlackRock reports beneficial ownership of 4,885,814 shares, representing 6.7% of Lexeo's outstanding common stock as of the event date 12/31/2025.
The filing states that BlackRock has sole power to vote 4,838,218 shares and sole power to dispose of 4,885,814 shares, with no shared voting or dispositive power. The shares are held by certain BlackRock business units in the ordinary course of business and are not held for the purpose of changing or influencing control of Lexeo. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Lexeo’s outstanding common shares.
Lexeo Therapeutics, Inc. reported positive interim Phase 1/2 clinical data for its gene therapy candidate LX2020 in PKP2-associated arrhythmogenic cardiomyopathy. On January 12, 2026, the company issued a press release describing these results and scheduled a conference call and webcast at 8:00 a.m. ET the same day to discuss the interim data. Lexeo also posted an updated LX2020-focused corporate presentation and a broader corporate presentation on its website, both of which, along with the press release, are attached as exhibits. The report includes standard cautionary language that future clinical progress, regulatory outcomes, and the company’s liquidity and capital resources are subject to significant risks and uncertainties.
Lexeo Therapeutics, Inc. (LXEO) CEO insider transaction shows a small sale of shares by the company’s chief executive officer and director. On 11/18/2025, the reporting person sold 1,127 shares of common stock in a single reported transaction at a weighted average price of $9.27 per share.
The company notes that the sale was made to cover tax obligations arising from the release of restricted stock units, which is a common administrative transaction for equity compensation. After this sale, the reporting person beneficially owned 240,991 shares of Lexeo common stock, including 128,357 restricted stock units, indicating that the individual continues to hold a substantial equity position in the company.
Lexeo Therapeutics, Inc. reported an insider stock sale by its Chief Medical Officer. On 11/18/2025, the officer sold 615 shares of common stock at a weighted average price of $9.27 per share, coded as a sale transaction. The company notes this sale was made to cover tax obligations related to the release of restricted stock units.
After this transaction, the officer beneficially owned 72,646 shares of Lexeo common stock, which includes 58,866 restricted stock units. The filing confirms this was a Form 4 filed by a single reporting person in the capacity of an officer.
Lexeo Therapeutics, Inc. (LXEO)11/18/2025, the officer sold 386 shares of common stock at a weighted average price of $9.27 per share. The company notes this was a sale to cover tax obligations arising from the release of restricted stock units (RSUs), rather than an open-market discretionary sale.
After this transaction, the officer beneficially owned 65,476 shares of Lexeo common stock, which the filing states includes 48,098 RSUs. The sale price resulted from multiple trades executed in a price range from $9.09 to $9.37 per share.
Lexeo Therapeutics (LXEO) Chief Legal Officer Form 4 filing reports a small insider sale tied to tax obligations. On 11/18/2025, the officer sold 549 shares of common stock in a sale to cover taxes due upon the release of restricted stock units. The weighted average sale price was $9.27 per share, based on multiple trades between $9.09 and $9.37.
After this transaction, the officer beneficially owns 68,381 shares of Lexeo Therapeutics common stock, which includes 49,607 restricted stock units. The filing states that detailed trade‑by‑trade pricing information will be provided upon request to the SEC staff, the company, or any security holder.
Lexeo Therapeutics, Inc. (LXEO) reported an insider transaction by its Chief Technical Officer on a Form 4. The officer sold 721 shares of common stock on 08/18/2025 at a weighted average price of $9.27 per share. The sale was made to cover tax obligations arising from the release of restricted stock units (RSUs). After this transaction, the officer beneficially owned 63,476 shares of Lexeo common stock, which includes 47,733 RSUs.
Lexeo Therapeutics (LXEO) filed a resale registration covering up to 1,250,015 shares of common stock. The shares are issuable upon exercise of outstanding pre-funded warrants held by a single selling stockholder and may be sold from time to time by that holder.
Lexeo is not selling any shares in this filing and will not receive proceeds from the selling stockholder’s sales. The company would receive nominal cash equal to the $0.0001 per-share exercise price only if the pre-funded warrants are exercised for cash; the warrants may also be exercised on a cashless basis under certain conditions.
The pre-funded warrants were issued in an October 2025 private placement at $7.9999 per warrant for aggregate proceeds of approximately $10 million. They are exercisable at any time, subject to a 9.99% beneficial ownership limit that the holder may reset up to 19.99% effective 61 days after notice. LXEO’s common stock trades on Nasdaq under “LXEO,” with a last quoted sale price of $8.35 on November 4, 2025.
Lexeo Therapeutics (LXEO) filed a Form S-8 to register 2,000,000 shares of common stock reserved for issuance under the 2025 Inducement Equity Incentive Plan. The plan is intended for equity awards granted as hiring inducements outside stockholder-approved plans.
This is an administrative registration to facilitate future employee equity awards, not a public offering. The filing includes customary legal opinions and consents.
Lexeo Therapeutics (LXEO) reported Q3 2025 results with a net loss of
As of September 30, 2025, cash, cash equivalents and investments in U.S. Treasury securities totaled
FAQ
What is the current stock price of Lexeo Therapeutics (LXEO)?
What is the market cap of Lexeo Therapeutics (LXEO)?
